Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Transfusion-dependent β-thalassaemia (TDβT) is a genetic disorder characterised by reduced or absent β-globin chain synthesis, resulting in chronic anaemia. Treatment consists of regular blood transfusions and chelation therapy to limit iron overload and its negative effects on organs (e.g. heart, lungs and liver). Despite improved life expectancy with transfusions and chelation therapy, TDβT patients experience poor quality of life and impaired exercise capacity (mainly due to muscle deconditioning and reduced cardiac inotropism). The aims of this review are (i) to discuss the role of organ dysfunction in the impairment of exercise capacity and reduced quality of life of TDβT patients; and (ii) to discuss physical activity as a potential therapeutic strategy to alleviate the multifactorial impact of the disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739766 | PMC |
| http://dx.doi.org/10.1111/bjh.19847 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The disease burden of β-thalassaemia revisited.
Hematology
December 2025
Thalassaemia International Federation (TIF), Nicosia, Cyprus.
Objective: The complexity of β-thalassaemia with associated morbidity, lifelong daily expensive treatment, and multidisciplinary care results in a considerable disease burden. Our study aimed to revisit the β-thalassaemia burden using epidemiological, clinical, and financial indicators related to patients, families, and healthcare systems.
Methods: Patient density measures, transfusion indices, complication rates, universal health coverage, and other indicators were tabulated by country and region.
Novel Red Blood Cell Exchange Parameters for Treatment of Transfusion-Dependent Thalassemia Based on Experience of Five Patients.
J Hematol
August 2025
Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, USA.
Background: Thalassemias are inherited red blood cell disorders characterized by defective globin production, resulting in microcytic hypochromic anemia. Severe variants lead to transfusion dependence and consequent iron overload, often despite chelation therapy. The role of automated red blood cell exchange (RBCX) for transfusion-dependent thalassemia (TDT) is unclear and previously there was no specific apheresis parameters specific for thalassemia defined.
View Article and Find Full Text PDFCase Report: Dual immunomodulatory and hematologic benefits of rituximab in refractory anemia of ANCA-associated vasculitis.
Front Immunol
September 2025
Department of Nephrology, Ningbo No.2 Hospital, Ningbo, Zhejiang, China.
Background: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune disease characterized by necrotizing small-vessel inflammation, frequently complicated by severe anemia and progressive renal injury. Anemia, affecting 73-92% of AAV patients, arises from multifactorial mechanisms including renal dysfunction, chronic inflammation, and iron dysregulation. Despite conventional immunosuppressive therapies, refractory anemia remains a significant challenge, with limited strategies targeting inflammation-driven hepcidin dysregulation.
View Article and Find Full Text PDFEvaluating the effect of chicory on serum ferritin levels in transfusion-dependent Β-thalassemia patients: a randomized clinical trial.
Ann Med Surg (Lond)
September 2025
Aliasghar Clinical Research Development Center, Department of Pediatrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Introduction: Several approved iron chelators exist, but they may cause significant adverse reactions in some patients. It is essential to explore complementary treatments that enhance compliance and minimize side effects.
Objectives: This study aims to evaluate the efficacy of chicory in reducing serum ferritin levels in transfusion-dependent β-thalassemia patients.
Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review.
J Med Econ
December 2025
Bristol Myers Squibb, Lawrenceville, NJ, USA.
Background: Erythropoiesis-stimulating agents (ESAs) are an established treatment for lower-risk myelodysplastic syndromes (LR-MDS). However, real-world data on the outcomes of patients with LR-MDS treated with ESAs are limited. This study describes treatment patterns and clinical outcomes in this population.
View Article and Find Full Text PDF